Smoking status and response to thiopurines in steroid-dependent inflammatory bowel disease

Inflammatory Bowel Diseases

Volumn 17, Issue 4, 2011, Pages 971-975

  Domènech, Eugeni ^a,b   Carrión, Sílvia ^a   Garcia Planella, Esther ^c   Mañosa, Míriam ^a,b   Gordillo, Jordi ^c   Concepción, Mar ^c   Guarner, Carlos ^b,c   Cabré, Eduard ^a,b  

^a HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

Author keywords

Azathioprine; Crohn's disease; Inflammatory bowel disease; Smoking; Thiopurines; Tobacco; Ulcerative colitis

Indexed keywords

6 MERCAPTOPURINE DERIVATIVE; AZATHIOPRINE; CYCLOSPORIN; INFLIXIMAB; MERCAPTOPURINE; STEROID;

ADULT; ARTICLE; COLON RESECTION; CONTROLLED STUDY; CROHN DISEASE; DISEASE COURSE; DRUG CHOICE; DRUG RESPONSE; DRUG TOLERANCE; DRUG WITHDRAWAL; EPIGASTRIC PAIN; FEMALE; FLU LIKE SYNDROME; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HUMAN; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; NAUSEA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REMISSION; SEX DIFFERENCE; SMOKING HABIT; TREATMENT DURATION; ULCERATIVE COLITIS; UNSPECIFIED SIDE EFFECT; VOMITING;

ADULT; AZATHIOPRINE; COLITIS, ULCERATIVE; CROHN DISEASE; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; SMOKING; STEROIDS; TREATMENT OUTCOME;

EID: 79952457655     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.21456     Document Type: Article

References (32)

1. Harries AD, Baird A, Rhodes J. Non-smoking: a feature of ulcerative colitis. Br Med J (Clin Res Ed). 1982;284:706. (Pubitemid 12176825)
2. Somerville KW, Logan RF, Edmond M, et al. Smoking and Crohn's disease. Br Med J (Clin Res Ed). 1984;289:954-956. (Pubitemid 14011155)
3. Calkins BM. A meta-analysis of the role of smoking in inflammatory bowel disease. Dig Dis Sci. 1989;34:1841-1854. (Pubitemid 20018648)
4. Mahid SS, Minor KS, Soto RE, et al. Smoking and inflammatory bowel disease: a meta-analysis. Mayo Clin Proc. 2006;81:1462-1471.
5. Cosnes J. Tobacco and IBD: relevance in the understanding of disease mechanisms and clinical practice. Best Pract Res Clin Gastroenterol. 2004;18:481-496. (Pubitemid 38667461)
6. Lakatos PL, Szamosi T, Lakatos L. Smoking in inflammatory bowel diseases: good, bad or ugly? World J Gastroenterol. 2007;130:6134-6139.
7. Parsi MA, Achkar JP, Richardson S, et al. Predictors of response to infliximab in patients with Crohn's disease. Gastroenterology. 2002; 123:707-713. (Pubitemid 34977076)
8. Vermeire S, Louis E, Carbonez A, et al. Demographic and clinical parameters influencing the short-term outcome of anti-tumor necrosis factor (infliximab) treatment in Crohn's disease. Am J Gastroenterol. 2002;97:2357-2363.
9. Arnott ID, McNeill G, Satsangi J. An analysis of factors influencing short-term and sustained response to infliximab treatment for Crohn's disease. Aliment Pharmacol Ther. 2003;17:1451-1457. (Pubitemid 36831435)
10. Fefferman DS, Lodhavia PJ, Alsahli M, et al. Smoking and immunomodulators do not influence the response or duration of response to infliximab in Crohn's disease. Inflamm Bowel Dis. 2004;10:346-351. (Pubitemid 39029176)
11. Rutgeerts P. Review article: recurrence of Crohn's disease after surgery - the need for treatment of new lesions. Aliment Pharmacol Ther. 2006;24(suppl 3):29-32. (Pubitemid 44326416)
12. Lennard-Jones JE. Classification of inflammatory bowel disease. Scand J Gastroenterol. 989;24-6(suppl 170):2-6.
13. Silverberg M, Satsangi J, Ahmad T, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal world congress of gastroenterology. Can J Gastroenterol. 2005;19(suppl A):5A-36A.
14. Ansari A, Arenas M, Greenfield SM et al. Prospective evaluation of the pharmacogenetics of azathioprine in the treatment of inflammatory bowel disease. Aliment Pharmacol Ther. 2008;28:973-983.
15. Cuffari C, Dassopoulos T, Turnbough L, et al. Thiopurine methyltransferase activity influences clinical response to azathioprine in inflammatory bowel disease. Clin Gastroenterol Hepatol. 2004;2: 410-417. (Pubitemid 38561239)
16. Smith MA, Marinaki AM, Arenas M, et al. Novel pharmacogenetic markers for treatment outcome in azathioprine-treated inflammatory bowel disease. Aliment Pharmacol Ther. 2009;30:375-384.
17. Mendoza JL, Urcelay E, Lana R, et al. MDR1 polymorphisms and response to azathioprine therapy in patients with Crohn's disease. Inflamm Bowel Dis. 2007;13:585-590. (Pubitemid 46799643)
18. Fraser AG, Orchard TR, Jewell DP. The efficacy of azathioprine for the treatment of inflammatory bowel disease: a 30 year review. Gut. 2002;50:485-489. (Pubitemid 34638866)
19. Lémann M, Mary JY, Duclos B, et al. Infliximab plus azathioprine for steroid-dependent Crohn's disease patients: a randomized placebo-controlled trial. Gastroenterology. 2006;130:1054-1061.
20. Gisbert JP, Niño P, Cara C, et al. Comparative effectiveness of azathioprine in Crohn's disease and ulcerative colitis: prospective, long-term, follow-up study of 394 patients. Aliment Pharmacol Ther. 2008; 28:228-238. (Pubitemid 351861969)
21. Saibeni S, Virgilio T, D'Incà R,et al. The use of thiopurines for the treatment of inflammatory bowel diseases in clinical practice. Dig Liver Dis. 2008;40:814-820.
22. Papay P, Reinisch W, Ho E, et al. The impact of thiopurines on the risk of surgical recurrence in patients with Crohn's disease after first intestinal surgery. Am J Gastroenterol. 2010;105:1158-1164.
23. Lakatos PL, Czegledi Z, Szamosi T, et al. Perianal disease, small bowel disease, smoking, prior steroid or early azathioprine/biological therapy are predictors of disease behavior change in patients with Crohn's disease. World J Gastroenterol. 2009;15:3504-3510.
24. Szamosi T, Banai J, Lakatos L, et al. Early azathioprine/biological therapy is associated with decreased risk for first surgery and delays time to surgery but not reoperation in both smokers and nonsmokers with Crohn's disease, while smoking decreases the risk of colectomy in ulcerative colitis. Eur J Gastroenterol Hepatol. 2010;22: 872-879.
25. Treton X, Bouhnik Y, Mary JY, et al. Azathioprine withdrawal in patients with Crohn's disease maintained on prolonged remission: a high risk of relapse. Clin Gastroenterol Hepatol. 2009;7:80-85.
26. Sokol H, Seksik P, Nion-Larmurier I, et al. Current smoking, not duration of remission, delays Crohn's disease relapse following azathioprine withdrawal. Inflamm Bowel Dis. 2010;16:362-363.
27. Cosnes J, Carbonnel F, Beaugerie L, et al. Effects of cigarette smoking on the long-term course of Crohn's disease. Gastroenterology. 1996;110:424-431. (Pubitemid 26043875)
28. Sutherland LR, Ramcharan S, Bryant H, et al. Effect of cigarette smoking on recurrence of Crohn's disease. Gastroenterology. 1990;98: 1123-1128. (Pubitemid 20143093)
29. Cosnes J, Nion-Larmurier I, Afchain P, et al. Gender differences in the response of colitis to smoking. Clin Gastroenterol Hepatol. 2004; 2:41-48. (Pubitemid 38165398)
30. Lindberg E, Järnerot G, Huitfeldt B. Smoking in Crohn's disease: effect on localisation and clinical course. Gut. 1992;33:779-782.
31. Karban A, Eliakim R. Effect of smoking on inflammatory bowel disease: is it disease or organ specific? World J Gastroenterol. 2007; 13:2150-2152.
32. Chaparro M, Ordás I, Cabré E, et al. Safety of thiopurine therapy in inflammatory bowel disease: long-term follow-up study of 3,900 patients. J Crohn's Colitis. 2010;4:S85.